Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR ‐mutated non‐small cell lung cancer patient: A case report

Our case reports an advanced EGFR ‐mutant lung adenocarcinoma patient achieved PR and a PFS of 6 months to a combination of immunotherapy and anti‐angiogenic agent, sintilimab and bevacizumab, as subsequent‐line therapy. Sintilimab and bevacizumab combination therapy was well‐tolerated and effective, resulting in dramatic tu mor reduction and improvement in clinical symptoms. A 53 ‐year‐old man diagnosed with disease stage IIIB pulmonary adenocarcinoma underwent chemotherapy and radiotherapy in the first‐line setting. After disease progression, he received targeted therapy because of subsequent detection ofEGFR exon 19 del mutation. Following an increase in his adrenal metastases, a combination of immunotherapy and antiangiogenic therapy (sintilimab plus bevacizumab) was commenced. After one month, imaging showed that the adrenal metastases had shrunk and a progression ‐free survival (PFS) of 6.0 months was achieved. In this case, we showed that the PD1 inhibitor sintilimab plus bevacizumab was effective in a refactory advancedEGFR‐mutant NSCLC with positive PD‐L1 expression.Key pointsOur case report provides clinical evidence of the durable response of a patient with advanced EGFR ‐mutant lung adenocarcinoma to a combination of immunotherapy and anti‐angiogenic agent, sintilimab and bevacizumab, as subsequent‐line therapy. Sintilimab and bevacizumab combination therapy was well‐tolerated and effective, resulting in dramatic tumor reduction and imp...

Source: Thoracic Cancer - July 12, 2020 Category: Cancer & Oncology Authors: Yiruo Zhang, Mei Zhao, Shuliang Cao, Xuchao Zhang, Yingying Du Tags: CASE REPORT Source Type: research